C4X Discovery Holdings PLC Board Change (2929U)
December 02 2021 - 1:00AM
UK Regulatory
TIDMC4XD
RNS Number : 2929U
C4X Discovery Holdings PLC
02 December 2021
C4X Discovery Holdings plc
("C4XD", "C4X Discovery" or the "Company")
Board Change
C4XD strengthens Board with the appointment of Dr Mario Polywka
as Harry Finch steps down
2 December 2021 - C4X Discovery Holdings plc (AIM: C4XD), a
pioneering Drug Discovery company, today announces the appointment
of Dr Mario Polywka as a Non-Executive Director to the Board of
Directors effective from 1 December 2021. Dr Polywka replaces Harry
Finch, Non-Executive Director who has confirmed that he will be
stepping down from the Board of Directors following the Annual
General Meeting which is expected to be held in January 2022.
Mario joins C4XD with more than 20 years' experience in
leadership roles across the biotech industry. Mario brings strong
operational, commercial, strategic and drug discovery expertise to
the Board. He was Chief Operating Officer of Evotec SE for 12
years, where he was involved with transactions worth more than
$1.0 billion within Evotec and Oxford Asymmetry International,
prior to becoming a Member of the Evotec Supervisory Board. In
addition, he holds a number of Non-Executive Board Director
positions in biotech companies including Exscientia, Forge,
Blacksmith Medicines and Orbit Discovery. Mario studied chemistry
at Oxford University, where he also completed a DPhil with
Professor Steve Davies and a postdoc with the late Professor Sir
Jack Baldwin. He is a Fellow of the Royal Society of Chemistry and
has published a number of papers in leading publications.
Eva-Lotta Allan, Chairman of C4X Discovery, said: " I'm
delighted to welcome Mario to C4XD. With his highly successful
career in biotech and his broad industry expertise, I am confident
he will contribute significantly to the C4XD Board of Directors,
and I look forward to working with Mario on the Board " .
" I would very much like to take th is opportunity to thank Harr
y on behalf of the Board for his guidance and deep commitment to
C4XD for the last 11 years. He has been an invaluable source of
support , not only to the Board, but also to the scientific and
commercial teams throughout the Company's formative years and we
wish him well with his new endeavour ."
Dr Mario Polywka commented: "I am excited to be joining C4XD at
this important time in the Company's growth. With two recent deals
with leading pharmaceutical companies, C4XD has clearly
demonstrated the strength of its science and its ability to
commercialise it. The C4XD Board and team are entrepreneurial, have
deep R&D expertise and are driven, and I am looking forward to
working closely with them ."
Additional Disclosures
The following information is disclosed pursuant to Schedule Two
paragraph (g) of the AIM Rules of Companies.
Dr Mario Polywka (aged 58) holds, or has held, the following
current and former directorships in the past five years:
Current Directorships Former Directorships in the past
five years
Blacksmith Medicines Inc. Aptuit (Oxford) Limited
---------------------------------
Evotec SE Aptuit (Potters Bar) Limited
---------------------------------
Exscientia Plc Cyprotex Discovery Limited
---------------------------------
Forge Therapeutics Inc. Cyprotex Limited
---------------------------------
Obit Discovery Ltd Euprotec Limited
---------------------------------
Orbit Discovery Group Ltd Evotec (UK) Limited
---------------------------------
Exscientia AI Limited
---------------------------------
Panion Limited
---------------------------------
Pharminox Ltd
---------------------------------
T-Cypher Bio Limited
---------------------------------
Save as set out above, no further information regarding Dr Mario
Polywka is required to be disclosed pursuant to Schedule Two
paragraph (g) of the AIM Rules for Companies.
- Ends -
Contacts
C4X Discovery Holdings
Mo Noonan, Communications +44 (0)787 6444977
Panmure Gordon (UK) Limited (NOMAD and
Broker)
Freddy Crossley, Emma Earl (Corporate
Finance) +44 (0)20 7886 2500
Rupert Dearden (Corporate Broking)
C4X Discovery Media - Consilium Strategic
Communications
Mary-Jane Elliott, Chris Gardner, Matthew
Neal +44 (0)203 709 5700
Notes to Editors:
About C4X Discovery
C4X Discovery ("C4XD") is a pioneering Drug Discovery company
combining scientific expertise with cutting-edge Drug Discovery
technologies to efficiently deliver world leading medicines, which
are developed by our partners for the benefit of patients. We have
a highly valuable and differentiated approach to Drug Discovery
through our enhanced DNA-based target identification and candidate
molecule design capabilities, generating small molecule drug
candidates across multiple disease areas including inflammation,
oncology, neurodegeneration and addictive disorders. Our
commercially attractive portfolio ranges from early stage novel
target opportunities to late stage Drug Discovery programmes ready
for out-licensing to partners and we have two commercially
partnered programmes with one candidate in clinical
development.
We collaborate with leading pharmaceutical and life sciences
companies to enrich our expertise and take our assets through
pre-clinical and clinical development. Through early-stage
revenue-generating licensing deals, we realise returns from our
high value pre-clinical assets which are reinvested to maximise the
value of our Drug Discovery portfolio.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAVFLFBFLLLFBB
(END) Dow Jones Newswires
December 02, 2021 02:00 ET (07:00 GMT)
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Apr 2024 to May 2024
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From May 2023 to May 2024